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Inhibition of EGFR Tyrosine Kinase by Erlotinib
Prevents Sclerodermatous Graft-Versus-Host Disease
in a Mouse Model
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Philippe Grange1, Bernard Weill1,2, Carole Nicco1,3 and Frédéric Batteux1,2,3
Chronic graft-versus-host disease (GVHD) follows allogeneic hematopoietic stem cell transplantation. It results
from alloreactive processes induced by minor histocompatibility antigen incompatibilities leading to the
activation of CD4 T cells and the development of ﬁbrosis and inﬂammation of the skin and visceral organs and
autoimmunity that resemble systemic sclerosis. EGFR is a ubiquitous cell receptor deeply involved in cell
proliferation, differentiation, and motility. EGFR has recently been implicated in autoimmune and ﬁbrotic
diseases. Therefore, we tested whether Erlotinib, an EGFR tyrosine kinase inhibitor, can prevent sclerodermatous
GVHD (Scl-GVHD). Scl-GVHD was induced in BALB/c mice by B10.D2 bone marrow and spleen cell
transplantation. Transplanted mice displayed severe clinical symptoms including alopecia, ﬁbrosis of the skin
and visceral organs, vasculitis, and diarrhea. The symptoms were reversed in mice treated with Erlotinib. These
beneﬁcial effects were mediated by the decreased production of activated/memory CD4+ T cells and the
reduction in T-cell inﬁltration of the skin and visceral organs along with a decrease in IFN-γ and IL-13 production
and autoimmune B-cell activation. The improvement provided by Erlotinib in the mouse model of Scl-GVHD
supplies a rationale for the evaluation of Erlotinib in the management of patients affected by chronic GVHD.
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INTRODUCTION
Chronic graft-versus-host disease (GVHD) is a side effect of
allogeneic hematopoietic stem cell transplantation, with
variable clinical presentations (Baird and Pavletic, 2006).
Chronic GVHD results from alloreactive processes induced
by minor major histocompatibility complex incompatibilities
between donor and recipient and involves donor-derived
immune cells and host cell populations. Its pathophysiology is
less well known than acute GVHD (Ferrara et al., 2009).
Chronic GVHD often mimics autoimmune diseases
(Filipovich et al., 2005). Initially, chronic GVHD was associ-
ated with a T helper type 2 (Th2)-type immune response, but
IFN and IL-17 seem implicated in its induction. Furthermore,
loss of immune tolerance by impaired thymic negative
selection allows expansion and activation of autoreactive T
and B cells from donor to induce chronic GVHD (Linhares
et al., 2013; Nishimori et al., 2013; Socié and Ritz, 2014).
Sclerodermatous GVHD (Scl-GVHD) represents 10 to 15% of
cases of chronic GVHD (Vogelsang et al., 2003). This clinical
form, similar to scleroderma, includes ﬁbrotic changes and
chronic inﬂammation of the skin, lung, and gastrointestinal
tract. Murine Scl-GVHD, produced by transplanting B10.D2
(H-2d) bone marrow and spleen cells across minor
histocompatibility loci into lethally irradiated BALB/cJ (H-2d)
recipients, displays many clinical and histologic similarities
with scleroderma (Jaffee and Claman, 1983). Syngeneic
(BALB/c into BALB/c) transplanted animals are used as
controls. This animal model summarizes the clinical features
of human Scl-GVHD including ﬁbrosis of the skin and inner
organs and inﬁltrating cutaneous mononuclear cells (pre-
dominantly T cells) starting 14 days following bone marrow
and splenocyte transplantation (Yamamoto, 2010).
We have observed in a mouse model of scleroderma that
angiotensin II elicits skin and visceral ﬁbrosis that can be
abrogated by angiotensin II receptor blockade using Irbesar-
tan (Marut et al., 2013). Angiotensin II increases ﬁbroblast
proliferation, myoﬁbroblasts differentiation, and the accumu-
lation of type I collagen through the phosphorylation of
Smad3, a transcription factor implicated in the activation of
the type I collagen gene, and through the activation of the
nicotinamide adenine dinucleotide phosphate oxidase and the
overproduction of reactive oxygen species (Yang et al., 2009).
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The latter phenomenon is responsible for EGFR phos-
phorylation. The transactivation of EGFR by angiotensin
initiates the proliferation and migration of ﬁbroblasts, a
phenomenon that can be abrogated by AT1 antagonist
(Yahata et al., 2006). This link between EGFR and ﬁbrosis
explains the attenuation of liver ﬁbrosis and of the develop-
ment of hepatocellular carcinoma by EGFR inhibition using
Erlotinib (Fuchs et al., 2014).
Erlotinib is a potent inhibitor of EGFR tyrosine kinase used
to treat advanced or metastatic non-small-cell lung cancer
after failure of ﬁrst-line or second-line chemotherapy (Akita
and Sliwkowski, 2003; Johnson et al., 2005; Robert, 2011). In
addition to its antiproliferative properties against tumor cells,
Erlotinib inhibits T-cell proliferation and Th1-cell–mediated
immune response in vitro and in vivo through the inhibition of
the c-Raf/extracellular signal–regulated kinase cascade and
the Akt signaling pathway (Luo et al., 2011).
As GVHD involves both Th1 cell–mediated immune response
and ﬁbrosis, we were prompted to investigate the effects of
Erlotinib on the development of chronic Scl-GVHD in mice.
RESULTS
Phospho-EGFR expression in mouse ears from GVHD animals
and modulation by Erlotinib
Levels of phospho-EGFR (pEGFR) were assessed by immuno-
histochemistry on ear pinna sections and by western blot on
lysates of ear lobes. pEGFR expression was greater in mouse
ear pinna that developed Scl-GVHD than in control mice
with a syngeneic graft (Figure 1a). This result was conﬁrmed
by western blot. pEGFR expression was increased by 32%
compared with syngeneic control mice (P= 0.043, Figure 1b).
Erlotinib decreased the expression of phospho-EGFR com-
pared with untreated GVHD mice (0.67± 0.019 vs. 0.53±
0.025 arbitrary unit (AU), P= 0.0027, Figure 1b).
Disease severity score
The clinical score assessment started 10 days after transplan-
tation. At day 23, no difference between groups was
observed. At day 26, the score of the GVHD group reached
1.11± 0.3 AU, whereas the score of the syngeneic group
remained null (Po0.0001, Figure 2a). At the time of killing on
day 33, a signiﬁcant improvement in the Erlotinib group was
observed versus untreated mice (2.39± 0.20 vs. 1.65± 0.10
AU, P= 0.047 at day 33, Figure 2a).
Skin involvement
At 7 days after transplantation, ear thickness was increased in
GVHD groups compared with syngeneic groups (30.0± 0.4
vs. 42.2± 0.8 μm, Po0.0001 at day 17, Figure 2b). From day
23, a decrease in earlobe thickening was observed in GVHD
mice treated with Erlotinib compared with untreated animals.
At the time of killing, the mean ear pinna thickness was lower
in Erlotinib-treated GVHD mice than in untreated mice
(45.9± 1.2 vs. 35.8± 1.4 μm, Po0.0001, Figure 2b). Sirius
red staining showed an increased collagen deposition in
GVHD mice pinna skin versus the three other groups
(Figure 2c).
Lymphocytic inﬁltration of the skin
Cellular inﬁltration of the skin of Erlotinib-treated GVHD
mice was lower than in untreated animals (3.80± 0.55 vs.
12.86± 0.88, P=0.0008, Figure 3a and b). Costaining with
phycoerythrin-labeled anti-CD3 mAb showed that green
donor cells were CD3-T lymphocytes (10.57± 0.48 vs.
3.00± 0.30, Po0.0001, Figure 3a and b). IFN-γ production
by inﬁltrating lymphocytes was signiﬁcantly increased in
GVHD mice compared with syngeneic mice (236.5± 73.3 vs.
5,828± 896 pgml− 1, Po 0.0001, Figure 3c). Erlotinib sig-
niﬁcantly decreased IFN-γ secretion (3,143± 463.7 vs.
5,828± 896.0 pgml− 1 in untreated animals, P=0.0178,
Figure 3c). IL-13 secretion in the skin signiﬁcantly increased
in GVHD mice compared with syngeneic mice (1,420± 241
vs. 124± 32 pgml−1, P= 0.0002, Figure 3c). Erlotinib
decreased IL-13 secretion (792± 180 vs. 1,420±241 pgml−1
in untreated animals, P= 0.036, Figure 3c). These results have
been conﬁrmed by quantitative real-time reverse-transcrip-
tase–PCR for IFN-γ and IL-13. IFN-γ mRNAs were higher in
the skin of GVHD mice than in syngeneic mice (7.69± 0.50-
foldvs. syngeneic mice, P= 0.0028, Figure 3d). Following
Erlotinib, IFN-γ mRNA levels in GVHD mice returned to
Syngeneic GVHa
0.4
0.5
0.6
0.7
0.8
*** *
Syn Syn-Erlo GVH GVH-Erlo
AU
pEGFR
β-Actin
Syn Syn Syn
Erlo
Syn
Erlo
GVHGVH GVH
Erlo
GVH
Erlo
b
pEGFR
Figure 1. Effects of Erlotinib on mouse ear skin following graft-versus-host
disease (GVHD) induction and oral administration of Erlotinib (Erlo).
(a) Immunohistochemical study of phospho-EGFR (pEGFR) on 7 μm ear skin
sections in syngeneic (Syn) BALB/c mice and in GVHD mice, revealed with
diaminobenzidine tetrahydrochloride. (b) Western blot of pEGFR expression in
the ear skin of BALB/c mice submitted to a syngeneic or a nonsyngeneic graft.
Photographs were taken with a Nikon Eclipse 80i microscope. Original
magniﬁcation × 50. Values in b are mean± SEM. *P≤0.05; ***P≤ 0.001.
AU, arbitrary unit.
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initial levels (1.03± 0.04-fold vs. 7.69± 0.50-fold in the
untreated GVHD group, P=0.0029, Figure 3d). IL-13 mRNAs
were increased in GVHD mice compared with syngeneic
(3.69± 0.07-fold vs. syngeneic mice, Po0.0001, Figure 3d).
This level was decreased following Erlotinib compared with
untreated mice (0.52± 0.04-fold vs. 3.69±0.07-fold in the
untreated GVHD group, Po0.0001, Figure 3d). CCL17
mRNAs were overexpressed in the skin of GVHD mice
compared with syngeneic mice (3.34± 0.54-fold vs. syn-
geneic mice, P= 0.0017). Erlotinib abolished the overexpres-
sion of CCL17 in GVHD mice (0.71± 0.41-fold vs.
3.34± 0.54-fold in the untreated GVHD group, P= 0.0026,
Figure 3d). Similarly, CCL21 mRNAs were higher in GVHD
mice than in syngeneic mice (6.51±0.29-fold vs. syngeneic
mice, P= 0.0016; Figure 3d). This mRNA level was decreased
in Erlotinib-treated GVHD mice compared with untreated
mice (1.23±0.10-fold vs. 6.51±0.29-fold in the untreated
GVHD group, P= 0.0020; Figure 3d). No difference in CCL27
mRNAs was found among the four groups (Figure 3d).
Prevention of GVHD-associated liver disease by Erlotinib
Serum alanine aminotransferase (ALT) and aspartate
aminotransferase (AST) were higher in GVHD -untreated
mice than in syngeneic groups (ALT: 184.6±31.15 vs.
55.7± 5.85 UI l− 1, Po0.05, and AST: 464.71± 79.37 vs.
160.33± 12.38 UI l−1, Po0.01, Figure 4b and c). Erlotinib
decreased transaminase levels in GVHD mice (ALT: 104.88±
12.60 vs. 184.57± 31.15UI l− 1, Po0.05, and AST: 291.25±
17.04 vs. 464.71± 79.37UI l− 1, Po0.05, Figure 4b and c).
Liver sections from untreated GVHD mice showed portal
inﬂammation and bile duct destruction (Figure 4a). GVHD
mice treated with Erlotinib displayed a signiﬁcant reduction in
liver lesions compared with untreated GVHD animals
(0.63± 0.12 vs. 2.01 ± 0.47 AU, Po0.05). Mice grafted with
syngeneic bone marrow and splenocytes, treated or not with
Erlotinib, showed no liver inﬂammation (0.25± 0.07 vs.
0.19± 0.08 AU, P=nonsigniﬁcant).
Effects of Erlotinib on B- and T-cell responses
Anti-DNA topoisomerase I autoantibodies were increased
in GVHD mice compared with untreated syngeneic mice
(Po0.001, Figure 5a). Erlotinib signiﬁcantly reduced the
levels of anti-DNA topoisomerase I autoantibodies (1.15±
0.23 vs. 2.65±0.82 AU, Po0.001, Figure 5a). Furthermore,
Erlotinib reduced the number of B cells by 43% in syngeneic
mice compared with the untreated group (Po0.001,
Figure 5b). No difference in B-cell counts was observed
between treated and untreated GVHD mice.
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Figure 2. Effects of Erlotinib (Erlo) on clinical features following graft-versus-host disease (GVHD) induction and oral administration of Erlotinib. (a) Evolution
of the GVHD score in the different groups during Erlotinib treatment. (b) Evolution of ear skin thickness during Erlotinib treatment. (c) Representative Sirius
red–dyed ear skin sections of 7 μm, showing ﬁbrosis in syngeneic (Syn) BALB/c mice and in GVHD mice, treated by Erlotinib or not. Photographs were taken
with a Nikon Eclipse 80i microscope. Original magniﬁcation × 50. Values in a and b are mean± SEM. *P≤0.05; ***P≤0.001. Bars represent mean± SEM. AU,
arbitrary unit.
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Similarly, CD4 T cells decreased by 40% in the Erlotinib-
treated syngeneic group compared with the untreated group
(Po0.05, Figure 5c). There was no effect on CD8 cell
numbers in treated and untreated syngeneic mice (Figure 5d).
If the levels of CD4 and CD8 T cells were signiﬁcantly
decreased in untreated GVHD mice compared with untreated
syngeneic animals (93 and 87%, respectively Po0.001,
Figure 5c and d), no signiﬁcant difference between the levels
of CD4 and of CD8 T cells was observed between treated and
untreated GVHD animals (Figure 5c and d ). There was an
increase in the percentages of CD4 and CD8 memory T cells
within CD4 and CD8 T-cell subsets in GVHD mice compared
with syngeneic animals (1.6± 1.4% vs. 83± 3%, Po 0.001,
Figure 5e and 50± 17% vs. 83± 7%, Po0.001, Figure 5f).
Erlotinib did not inﬂuence the percentage of CD4+ and CD8+
T cells in the syngeneic group (Figure 5e and f). Erlotinib
induced an increase in percent CD4 naive T cells in GVHD
mice compared with untreated mice (45% vs. 17±1.6±
1.4%, Po0.001, Figure 5e), whereas it had no effect on CD8
naive T cells.
DISCUSSION
Here we show that Scl-GVHD is associated with an activation
of the EGFR pathway whose inhibition by the tyrosine kinase
inhibitor Erlotinib prevents skin and visceral lesions through
an inhibition of the allogeneic response.
Experimental chronic GVHD shares characteristic features
with scleroderma, including skin and visceral ﬁbrosis,
inﬂammation with systemic sclerosis, and autoimmunity.
Erlotinib improves the clinical outcome of sublethally
irradiated BALB/c mice transplanted with B10.D2 hemato-
poietic cells. Fibrosis, alopecia, and vasculitis are clearly
reduced in treated versus untreated mice. EGFR is a
ubiquitous cell receptor involved in proliferation, differentia-
tion, and cell motility (Schneider and Wolf, 2009). This
receptor has a role in tissue ﬁbrosis through the control of
ﬁbroblast proliferation and migration (Pastore et al., 2008).
Moreover, EGFR signaling promotes ﬁbrosis through a trans-
forming growth factor-β–dependent mechanism, implicating
activation of smad2/3 in various tissues like kidney or skin.
This could explain why EGFR inhibition by Erlotinib attenu-
ates liver ﬁbrosis and the development of hepatocellular
carcinoma (Fuchs et al., 2014).
Liver involvement is a common feature in human GVHD
that also occurs in the Scl-GVHD model (Jaffee and Claman,
1983; Lee et al., 2002). Indeed, in GVHD mice, we found
a periportal lymphocytic inﬁltration associated with an
increase in serum transaminase levels. Erlotinib decreased
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Figure 3. Effects of Erlotinib (Erlo) on mouse skin following graft-versus-host disease (GVHD) induction and oral administration of Erlotinib. (a) Representative
5 μm frozen skin sections with enhanced green ﬂuorescent protein (eGFP) donor cells and phycoerythrin-conjugated anti-CD3 mAb staining. (b) Scores obtained
by enumerating eGFP- and anti-CD3-positive cells in 10 areas per frozen skin section. (c) Levels of IFN-γ and IL-13 produced by skin cells and used as
markers of T helper type 1 and 2 (Th1 and Th2) responses. (d) Levels of mRNAs for IFN-γ, IL-13, CCL17, CCL21, and CCL27 in the skin. Photographs
were taken with a Nikon Eclipse 80i microscope. Original magniﬁcation: × 100. Values in b, c, and d are mean± SEM. *P≤0.05; **P≤ 0.01; ***P≤0.001.
qRT-PCR, quantitative real-time reverse-transcriptase–PCR; Syn, syngeneic.
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transaminase levels and reduced the periportal lymphocytic
inﬁltrate. Thus, in addition to its direct antiﬁbrotic properties
(Fuchs et al, 2014), Erlotinib inhibits the EGFR pathway and,
consecutively, abrogates tissue inﬁltration and inﬂammation
of the liver.
The pathophysiology of chronic GVHD is still poorly
understood. However, evidence suggests that, unlike acute
GVHD that is CD8+ T-cell dependent, the events observed in
chronic GVHD depend on the activation of donor CD4+
T cells speciﬁc of minor histocompatibility antigen (Korngold
and Sprent, 1978; Kansu, 2004; Shlomchik, 2007; Chu and
Gress, 2008). After transplantation of spleen and bone
marrow cells, naive CD4+ T cells from B10.D2 initiate the
disease in irradiated BALB/c mice. Activated donor CD4+
T cells inﬁltrate the skin and induce ﬁbrosis (Korngold and
Sprent, 1978; Kansu, 2004; Chu and Gress, 2008). In our
hands, the beneﬁcial effect of Erlotinib was associated with a
reduction in the percentages of effector memory CD4+ T cells
(CD69−CD4+CD44highCD62Llow) but not of CD8+ T cells in
GVHD mice.
This reduction is associated with a diminution in inﬁltrating
T cells in the skin and with a profound decrease in CCL17 and
CCL21 expression. Increased CCL17 mRNAs have already
been shown by Zhou et al. (2007) in murine Scl-GVHD.
CCL17 is the ligand of CCR4 on Th2 cells, basophils, and
natural killer cells. CCL17 produced by dendritic cells,
keratinocytes, ﬁbroblasts, and endothelial cells (Saeki and
Tamaki, 2006) has been implicated in various skin diseases
such as atopic dermatitis and bullous pemphigoid (Furudate
et al., 2014; Hamilton et al., 2014). CCL21 is the ligand of
CCR7 expressed by T cells, B cells, and dendritic cells
(Comerford et al., 2013). It has been implicated in contact
allergic dermatitis (Eberhard et al., 2004).
In addition to its antiproliferative properties against tumor
cells, Erlotinib exerts inhibitory effects on T-cell proliferation.
Erlotinib causes G0/G1 arrest and inhibits the secretion of IL-2
and the phosphorylation of c-Raf, extracellular signal–
regulated kinase, and Akt (Luo et al., 2011). Erlotinib acts as
other antiproliferative molecules like steroids, cyclosporine,
sirolimus, or mycophenolate that are treatments for chronic
GVHD (Wolff et al., 2010, 2011 ). Erlotinib impairs Th1-
mediated immune response as it inhibits the secretion of IFN-γ
by activated T cells in vitro and ameliorates in vivo picryl
chloride–induced ear contact dermatitis (Luo et al., 2011).
IFN-γ is involved in the pathophysiology of chronic GVHD
(Korholz et al., 1997; Bruggen et al., 2014). It induces an
overexpression of HLA and adhesion molecules in target
tissues and favors the recruitment of macrophages. Therefore,
its inhibition by Erlotinib can participate in the improvement
of GVHD. Recently, the immunomodulating role of Erlotinib
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Figure 4. Effects of Erlotinib (Erlo) on liver involvement following graft-versus-host disease (GVHD) induction and oral administration of Erlotinib.
(a) Hematoxylin–eosin staining of liver sections. GVH and GVH Erlo groups showed mixed lymphomonocytic inﬁltrations around the portal vein with a major
reduction in the GVH Erlo group. (b) Serum aspartate aminotransferase (AST) levels in various experimental groups. (c) Serum alanine aminotransferase (ALT)
levels in various experimental groups. Photographs were taken using a Nikon Eclipse 80i microscope. The arrows showed mixed lymphocytic inﬁltrations around
the portal vein. Original magniﬁcation × 100. Values in b and c are mean± SEM. *P≤0.05. Syn, syngeneic.
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was observed following the treatment of head and neck
squamous cell carcinoma by an EGFR inhibitor that induces
the production of transforming growth factor-β and
prostaglandin E2 by the tumor cells that attenuate antitumor
immune responses (Kumai et al., 2014). Therefore, the
immunomodulating effects of Erlotinib associate intrinsic
effects on T-cell signaling and extrinsic effects through
paracrine immunomodulating signals from another target
cell population. In addition to IFN-γ, IL-13 is also highly
expressed in the skin of GVHD mice. Erlotinib decreases the
production of IL-13 in their skin. Following the graft of B10.
D2 lymphoid cells into irradiated BALB/c mice, an increase in
the expression of type 2 cytokines in the skin of Scl-GVHD
mice has already been observed (Zhou et al., 2007).
Moreover, in other chronic GVHD models, induction of
GVHD ﬁbrosis of the skin and of visceral organs requires type
2 immune responses. Consequently, the reduced production
of IL-13 in our model probably contributes to the amelioration
of skin ﬁbrosis.
Chronic GVHD is associated with the production of
autoantibodies consecutive to the production of Th2 cyto-
kines (Ruzek et al., 2004; Kavian et al., 2012). In line with
previous reports, we observed a production of anti-DNA-
topoisomerase I antibodies in Scl-GVHD mice that was
decreased by Erlotinib. We conclude that Erlotinib targets
CD4+ T cells, blocks T- and B-cell cooperation in Scl-GVHD
mice, and prevents the development of autoimmunity in
our model.
This work highlights the role of the EGF receptor pathway
in the pathophysiology of Scl-GVHD. The inhibition of EGFR
phosphorylation by Erlotinib reduces tissue inﬂammation and
ﬁbrosis, limits the production of speciﬁc autoantibodies, and
prevents the production of CD4+memory T cells. Inhibition of
the EGFR pathway acts on the three main components of Scl-
GVHD: ﬁbrosis, inﬂammation, and autoimmunity. These
mechanisms explain the beneﬁcial effects of Erlotinib
observed and evidence the possible usefulness of this
molecule for the treatment of chronic GVHD in humans.
MATERIALS AND METHODS
Animals, cells, and chemicals
Six-week-old female BALB/c mice (Janvier Laboratory, Le Genest
Saint Isle, France) and male B10.D2-enhanced green ﬂuorescent
protein (eGFP) mice (gift from Colette Kanellopoulos-Langevin,
CDTA–CNRS–Orléans, France) were used in all experiments.
Animals received humane care according to the guidelines of our
institution (Inserm and Université Paris Descartes—CEEA34 Ethics
committee). All mice were housed in ventilated cages with sterile
food and water ad libitum. All cells were cultured as reported
previously (Kavian et al., 2010). All chemicals were obtained
from Sigma-Aldrich (St Louis, MO), except for Erlotinib (Roche
Registration, Meylan, France).
Experimental procedure for induction of GVHD in BALB/c mice
GVHD following splenocyte and bone marrow transplantation was
induced in BALB/c mice (H-2d; Janvier Laboratory) by grafting cells
from 7- to 8-week-old male B10.D2-eGFP mice (H-2d; Janvier
Laboratory), as previously described (Kavian et al., 2012). Brieﬂy,
recipient mice were lethally irradiated with 750 cGy from a
Gammacel [137Cs] source. After 3 hours, they were injected
intravenously with donor spleen cells (5.106 per recipient) and
bone marrow cells (2.106 per recipient), previously treated with a
hypotonic solution of potassium acetate for red blood cell lysis and
suspended in RPMI-1640. A control group of BALB/c recipient mice
received syngeneic BALB/c spleen and bone marrow cells (syngeneic
bone marrow transplantation, referred to as control animals).
Treatment of Scl-GVHD mice with Erlotinib
Scl-GVHD and control mice were randomized and treated per os
5 days a week for 4 weeks with either Erlotinib (50 mg kg− 1 per day)
or vehicle (methylcellulose 1%) alone, beginning on day 7 after bone
marrow transplantation (9 mice per group). Animals were killed by
cervical dislocation 7 weeks after transplantation.
Disease severity score
To determine the incidence and severity of disease, we assigned
a score to each mouse using the following criteria: 0: no external
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Figure 5. Inhibition of the production of autoantibodies in mice with graft-
versus-host disease (GVHD) systemic sclerosis treated in vivo with Erlotinib
(Erlo). Inhibition of the production of T cells with sclerodermatous GVHD (Scl-
GVHD) treated in vivo with Erlotinib. (a) Levels of anti-topoisomerase I
antibodies (Abs), as measured by ELISA. (b) Splenic B-cell numbers, as
assessed by ﬂow cytometry. (c) Splenic CD4 T-cell numbers, as assessed by
ﬂow cytometry. (d) Splenic CD8 T-cell numbers, as assessed by ﬂow
cytometry. (e) Ratio between naive and memory CD4 cells. (f) Ratio between
naive and memory CD8 cells. Values in a–f are mean± SEM. *P≤0.05;
***P≤0.001. AU, arbitrary unit; NS, nonsigniﬁcant; Syn, syngeneic.
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sign; 1: piloerection on back and underside, 1: hunched posture
or lethargy; 0.5: alopecia o1 cm2; 1: alopecia 41 cm2; 1: vasculitis
(one or more purpural lesions on ears or tail); and 1: eyelid sclerosis
(blepharophymosis). The severity score is the sum of these values and
ranges from 0 (unaffected) to a maximum of 6. The incidence and
severity score were recorded every week by two blinded scientists.
Skin thickness
Skin thickness of the right and left ears lobes of mice was measured
each week with a digital calliper and expressed in mm.
Histopathological analysis
Liver and skin pieces ﬁxed in formol were embedded in parafﬁn.
Then, 5-mm-thick tissue sections were stained with hematoxylin and
eosin or Picrosirius Red. Slides were examined by standard bright-
ﬁeld microscopy (Olympus BX60, Rungis, France) by a pathologist
who was blinded to the experimental group assignment.
Skin collagen content
Skin pieces were dilacerated using a scalpel, put into tubes, thawed,
and mixed with pepsin (1:10 weight ratio) and 0.5 M acetic acid
overnight at room temperature under stirring. The assay of collagen
content was based on the quantitative dye-binding Sircol method
(Biocolor, Belfast, Ireland).
Immunohistochemistry of pEGFR proteins in mouse ear skin
Sections of ear pinna, 7 μm thick, were placed onto slides,
deparafﬁnized, and then rehydrated. Antigen retrieval, endogenous
peroxidase blocking, and nonspeciﬁc binding blocking were
performed as previously described (Marut et al., 2013). Sections
were then incubated with 1:50 rabbit polyclonal anti-pEGFR (Y1092)
(ab40815, Abcam, Paris, France) overnight at 4 °C. Incubation with
horseradish peroxidase–labeled secondary goat anti-rabbit and
staining with diaminobenzidine tetrahydrochloride were performed
as previously described (Marut et al., 2013). Pictures were taken with
a digital camera on a BX60 microscope (Olympus), using DP
Manager Software, at ×100 magniﬁcation. Immunostaining was
analyzed using ImageJ software (version 1.36; National Institutes of
Health, Bethesda, MD) for quantitative assessment of staining
positivity. Results are expressed as percentages of positive skin area
analyzed with ImageJ software.
Western blot of pEGFR proteins in mouse ears skin
Skin fragments of earlobes were incubated with 250 μl of RIPA buffer
for western blot. Protein extracts (30 μg total protein) were resolved as
previously described (Marut et al., 2013). Blots were incubated
overnight at 4 °C with a 1:500 rabbit polyclonal anti-pEGFR (Y1092)
(ab40815, Abcam). Revelation and analysis were performed as
previously described (Marut et al., 2013). Results are expressed as
AU, deﬁned as the ratio between the densitometric intensity of the
bands of the proteins tested and bands labeled with mouse anti-β-
actin mAb.
Liver inﬂammation
At the time of killing, livers were removed from all mice in both
groups and kept in formol. Fixed liver pieces were embedded in
parafﬁn and stained with hematoxylin and eosin by standard
procedure. Slides were examined by standard bright-ﬁeld
microscopy (Olympus BX60) by a pathologist who was blinded to
the experimental group assignment. Degree of inﬂammation of
coded microscopic sections of liver was graded from 0 to 4, as
previously described (Nagler et al., 2000).
Serum AST and ALT activities
Serum activity of AST and ALT were used as markers of hepatocyte
cytolysis. AST and ALT activities were quantiﬁed using a standard
clinical automatic analyser (Modular PP, Roche Diagnostics, Meylan,
France).
Immunohistochemistry of skin tissue sections
Frozen skin tissue sections of 5 μm thickness were stained for 1 hour
at room temperature with 1:50 phycoerythrin-labeled hamster
anti-mouse CD3 (clone 145-2C11; BD Bioscience, San Jose, CA) or
with the respective phycoerythrin-labeled control isotype (BD
Bioscience). After extensive washing in phosphate-buffered saline,
slides were viewed with an Olympus microscope equipped with an
epiﬂuorescence system to view eGFP- and phycoerythrin-labeled
cells. Images were collected using a digital camera with × 400
magniﬁcation objective. Hematopoietic donor cells appear in green
(B10.D2-eGFP) and in red for CD3+ T cells.
Determination of IFN-γ and IL-13 production in the skin
Punch biopsies (6 mm diameter) from the skin of each mouse were
incubated for 72 hours at 37 °C in complete RPMI medium with
5 μg ml−1 concanavalin A. Supernatants were collected and frozen
at − 80 °C. Cytokine concentrations from 1:4 diluted supernatants
were measured by ELISA. “Mouse IFN gamma ELISA Ready-SET-Go!”
and “Mouse IL-13 ELISA Ready-SET- Go!” kits were purchased from
eBioscience (San Diego, CA). Concentrations were calculated from a
standard curve according to the manufacturer’s protocol. Results are
expressed in pg ml− 1.
Determination of IL-13, IFN-γ, CCL17, CCL21, and CCL27
mRNA levels in the skin
RNA isolation was realized as described by Grange et al. (2009).
Ampliﬁcation was achieved with 50 ng of total RNA for each sample.
Real-time PCR was carried out with iTaq Universal SYBR Green
One-Step Kit (Bio-Rad, Hercules, CA). We used the 5′-GCTTGCC
TTGGTGGTCTCGCC-3′ and 5′-GGGCTACACAGAACCCGCCA-3′
primers for IL-13, the 5′-CAGCAACAGCAAGGCGAAAAAGG-3′ and
5′-TTTCCGCTTCCTGAGGCTGGAT-3′ primers for IFN-γ, the 5′-GG
TACCATGAGGTCACTTCAGA-3′ and 5′-CACTCTCGGCCTACATT
GGT-3′ primers for CCL17, the 5′-GGGAAACAAAGCCCCGG-3′
and 5′-GCTGTGTCTGTTCAGTTCTCTTG-3′ primers for CCL21, the
5′-CTGCTGAGGAGGATTGTC-3′ and 5′-CACGACAGCCTGGAG
GTGA-3′ primers for CCL27, and the 5′-TGCCGAGGATTTGG
AAAAAG-3′ and 5′-CCCCCCCTTGAGCACACAG-3′ primers for
HRPT that was used as a control.
Serum anti-DNA topoisomerase I autoantibodies
Levels of anti-DNA topoisomerase I IgG antibodies were assayed by
ELISA using puriﬁed calf thymus DNA topoisomerase I bound to the
wells of a microtiter plate (Abnova, Taipei City, Taiwan). Mouse
serum (1:4) and 1:1,000 anti-murine Ig horseradish peroxidase
(Dako, Glostrup, Denmark) secondary antibody were used as
previously described (Servettaz et al., 2009; Kavian et al., 2012).
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Flow cytometric analysis of spleen cell subsets
Cell suspensions from spleens were prepared after hypotonic lysis of
erythrocytes in potassium acetate solution. Cells were incubated with
the appropriate labeled antibody at 4 °C for 30minutes in phosphate-
buffered saline with 2% normal fetal calf serum. Flow cytometry was
performed using a FACS Fortessa ﬂow cytometer (BD Biosciences),
according to standard techniques. The mAbs used in this study
were anti-B220-PECy7, anti-CD11b-biotin and Streptavidin-PerCP,
anti-CD11c-PE on one hand and anti-CD69-BV421, anti-CD44-PE,
anti-CD62L-APC, anti-CD4-PerCP, and anti-CD8-PE-Cy7 (BD
Biosciences) on the other hand. Data were analyzed with FlowJo
software (Tree Star, Ashland, OR).
Statistical analysis
All quantitative data are expressed as mean± SEM. Data were
compared using one-way analysis of variance followed by
Dunn’s multiple comparison test. Student’s unpaired t-test was used
when comparing two groups. All analyses were carried out using the
GraphPad Prism 5.0 statistical software package (San Diego, CA),
and P-values of o0.05 were considered signiﬁcant.
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